Silodosin shows promise as on-demand oral contraceptive for men

  • Bhat GS & al.
  • World J Urol
  • 10 May 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Silodosin (Rapaflo) prevents unintended pregnancies in women who are the partners of men using it as an on-demand oral contraceptive.

Why this matters

  • This study is the first to assess silodosin, an approved treatment for benign prostatic hyperplasia (BPH), as an on-demand, reversible, nonhormonal, nonbarrier method of contraception for men, say researchers.

Study design

  • Researchers studied healthy, sexually active men in stable sexual relationships with fertile female partners (N=63) not using other contraceptive methods.
  • They randomly assigned patients to receive either silodosin 8 mg or placebo 3 hours before masturbation for 30 days, analyzing postmasturbation semen and postejaculation urine for spermatozoa.
  • Then, for 1 year, they provided all patients silodosin 8 mg for use 3 hours before vaginal intercourse.
  • Funding: None disclosed.

Key results

  • During the first part of the study, men receiving silodosin had no spermatozoa in either postmasturbation semen or postejaculation urine.
  • During the second part, no men or their partners reported unintended pregnancies.

Limitations

  • This was a pilot study with a small sample size.
  • Changes in semen volume might have made patients aware of switching from placebo to silodosin despite blinding.